TirzepatideDual GIP+GLP-1 Receptor Co-Agonist Research Reference by QSC Peptides

Tirzepatide is a 39-amino-acid synthetic peptide designed as a dual GIP and GLP-1 receptor co-agonist — the first member of the "twincretin" class. It was engineered around the GIP peptide scaffold with modifications enabling simultaneous binding to both GIPR (native-like affinity) and GLP-1R (~5× weaker than native GLP-1 at GLP-1R, which prevents hypoglycemia while preserving efficacy).

A C18 fatty diacid moiety enables albumin binding, extending plasma half-life to approximately 5 days. DPP-IV-resistant substitutions protect the N-terminus from plasma degradation.

GIP Receptor (GIPR) — The New Addition

GIPR, a Gs-coupled GPCR, was historically considered less important than GLP-1R in metabolic research. Tirzepatide revealed that GIPR agonism at physiological-like levels produces:

• Enhanced insulin sensitization: GIPR on adipocytes improves insulin-stimulated glucose uptake
• Adipocyte fat oxidation: GIP-stimulated cAMP → PKA → HSL activation in fat cells
• Synergistic GLP-1R amplification: Tirzepatide's GIPR activity sensitizes GLP-1R signaling through unknown cross-talk mechanisms
• Central appetite modulation: GIPR in hypothalamus and brainstem contributes independently to energy intake suppression

Why Tirzepatide Outperforms Semaglutide

The dual receptor mechanism explains Tirzepatide's superior weight reduction (~20–22% vs ~15–17% for semaglutide). The additive GIPR pathway contributes an estimated 5–7 percentage points of additional weight reduction beyond GLP-1R alone, driven by fat oxidation, insulin sensitization, and possible central effects separate from the GLP-1 axis.